Find helpful resources about Boston Scientific’s Drug-Eluting Technologies.

Anchor component is added but not authored

Case Study Videos

Treatment of a 76-year-old male patient with right anterior tibial and tibio-peroneal trunk occlusions using the Ranger™ Drug-Coated Balloon.

Click here to get access to the full-length case study video now.

April 10, 2017 
The video shows the diagnostic work-up with antegrade infusion, which finds a heavily diseased right SFA and short sub-total occlusion of an existing stent. 
January 18, 2017
Advances in Drug-Eluting Technologies used for the treatment of coronary artery disease have been adapted for application in chronic peripheral lesions.
January 18, 2017

Webcasts

              
Watch leading physicians discuss how drug-eluting therapies are revolutionizing the treatment of SFA lesions.
September 9, 2016

Expert Commentary

                                             
New 3-year data presented on the MAJESTIC trial; review of several challenging case studies; and more in the CIRSE Drug Eluting Symposium.
Watch the recordings
September 17, 2017
                                             
Watch Dr. Juan Granada discuss the latest Ranger preclinical data confirming the benefit of optimized drug transfer.
September 22, 2016
                                             
President CV Path Institute
"The longer you have kept the drug in, the better the results are going to be… it's a delicate balance of the total amount of drug you deliver, and for how long you deliver."
Read the article on Drug Delivery written by Prof. Stefan Müller-Hülsbeck: Eluvia™ peripheral stent system for the treatment of peripheral lesions above the knee.
January 26, 2017

Product Videos and Animation

Learn about Eluvia's unique polymer-based technology designed to sustain drug release to match restenosis in the SFA.
September 9, 2016
Learn about Ranger's innovative TransPax coating technology.
September 9, 2016
Discover how the Eluvia Stent was designed and engineered to solve the unique challenge of restenosis in the SFA.
September 9, 2016
Discover how the Ranger™ coating technology (TransPax) is designed to deliver a therapeutic drug dose consistently and efficiently to the lesion.
September 9, 2016

Brochures

Ranger SFA Registry
New 3-year data presented on the MAJESTIC trial; review of several challenging case studies; and more in the CIRSE Drug Eluting Symposium. Click here to watch.


Favorable twelve-month data for RANGER

Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.

May 24, 2017

DOWNLOAD RANGER 12 MONTH DATA SHEET


The RANGER™ SFA trial exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.
April 25, 2017

Articles

Endovascular Today, 2017

Download the Endovascular Today supplement and find out more on Drug-Eluting Technologies - Choosing the best option through data-informed decission making.

Endovascular Today 2017 Supplement

Endovascular Today, 2016

Download the Endovascular Today supplement and find out in a  series of 12 articles how drug-eluting therapies are shaping a new era of endovascular interventions.

Endovascular Today 2016 Supplement

About Drug-Eluting Technologies
Clinical Program
Resources Center
News & Events

WANT TO KNOW MORE?

Join our Drug-Eluting Technologies Community

Sign Up for Product Updates

Receive the latest news of Drug Eluting Technologies

SIGN UP